Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing

  • Prothena Corporation plc PRTA has dosed the first patient in the Phase 2b PADOVA study evaluating prasinezumab in patients with early Parkinson's disease.
  • Prasinezumab is an anti-alpha synuclein antibody.
  • The event has triggered a $60 million milestone to Prothena from its worldwide collaboration with Roche Holding AG RHHBY.
  • Prothena has previously received $75 million in payments from Roche as part of this collaboration.
  • PADOVA is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of prasinezumab in patients with early Parkinson's disease who are on stable symptomatic medication.
  • The study will enroll approximately 575 patients. The primary endpoint is time to meaningful progression on motor signs of the disease, as assessed by over 5 point increase from baseline in the Parkinson's Disease score.
  • Price Action: PRTA shares closed 5% lower at $23.39 on Monday.
Loading...
Loading...
PRTA Logo
PRTAProthena Corp PLC
$7.186.92%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
5.19
Growth
-
Quality
-
Value
81.47
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...